Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

[Janus kinase inhibitors : State of the art in clinical use and future perspectives].

Alten R, Mischkewitz M, Stefanski AL, Dörner T.

Z Rheumatol. 2020 Apr;79(3):241-254. doi: 10.1007/s00393-020-00768-5. Review. German.

PMID:
32219519
2.

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study.

Deodhar A, Strand V, Conaghan PG, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Alten R.

BMC Rheumatol. 2020 Mar 2;4:19. doi: 10.1186/s41927-020-0118-z. eCollection 2020.

3.

[Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].

Alten R, Mischkewitz M, Nitschmann S.

Internist (Berl). 2020 Mar 4. doi: 10.1007/s00108-020-00766-4. [Epub ahead of print] German. No abstract available.

PMID:
32130437
4.

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.

Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH.

Drugs. 2020 Feb;80(2):99-113. doi: 10.1007/s40265-020-01256-5.

5.

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.

Cohen SB, Radominski SC, Kameda H, Kivitz AJ, Tee M, Cronenberger C, Zhang M, Hackley S, Rehman MI, von Richter O, Alten R.

BioDrugs. 2020 Apr;34(2):197-207. doi: 10.1007/s40259-019-00403-z.

PMID:
31939063
6.

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.

Genovese MC, Glover J, Greenwald M, Porawska W, El Khouri EC, Dokoupilova E, Vargas JI, Stanislavchuk M, Kellner H, Baranova E, Matsunaga N, Alten R.

Arthritis Res Ther. 2019 Dec 12;21(1):281. doi: 10.1186/s13075-019-2046-0.

7.

Physical and Emotional Burden of Rheumatoid Arthritis: Data from RA Matters, a Web-Based Survey of Patients and Healthcare Professionals.

Alten R, van de Laar M, De Leonardis F, Tietz N, Guerreiro M, van Vollenhoven R.

Rheumatol Ther. 2019 Dec;6(4):587-597. doi: 10.1007/s40744-019-00179-2. Epub 2019 Oct 28.

8.

Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.

Peichl P, Alten R, Galeazzi M, Lorenz HM, Nüßlein H, Navarro F, Elbez Y, Chartier M, Hackl R, Rauch C, Connolly SE.

Wien Med Wochenschr. 2020 Apr;170(5-6):132-140. doi: 10.1007/s10354-019-00710-8. Epub 2019 Oct 25.

PMID:
31654156
9.

Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis.

Zrubka Z, Gulácsi L, Brodszky V, Rencz F, Alten R, Szekanecz Z, Péntek M.

Expert Rev Pharmacoecon Outcomes Res. 2019 Oct;19(5):537-549. doi: 10.1080/14737167.2019.1647104. Epub 2019 Aug 1.

PMID:
31340686
10.

Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.

Alten R, Feist E, Lorenz HM, Nüßlein H, Voll RE, Chartier M, Elbez Y, Rauch C.

Clin Rheumatol. 2019 Nov;38(11):3049-3059. doi: 10.1007/s10067-019-04648-5. Epub 2019 Jul 12.

PMID:
31300979
11.

New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study.

Englbrecht M, Alten R, Aringer M, Baerwald CG, Burkhardt H, Eby N, Flacke JP, Fliedner G, Henkemeier U, Hofmann MW, Kleinert S, Kneitz C, Krüger K, Pohl C, Schett G, Schmalzing M, Tausche AK, Tony HP, Wendler J.

PLoS One. 2019 May 28;14(5):e0217412. doi: 10.1371/journal.pone.0217412. eCollection 2019.

12.

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.

Alten R, Batko B, Hala T, Kameda H, Radominski SC, Tseluyko V, Babic G, Cronenberger C, Hackley S, Rehman M, von Richter O, Zhang M, Cohen S.

RMD Open. 2019 Mar 28;5(1):e000876. doi: 10.1136/rmdopen-2018-000876. eCollection 2019.

13.

Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.

Alten R, Mariette X, Lorenz HM, Nüßlein H, Galeazzi M, Navarro F, Chartier M, Heitzmann J, Poncet C, Rauch C, Le Bars M.

Clin Rheumatol. 2019 May;38(5):1535. doi: 10.1007/s10067-019-04545-x.

PMID:
30972577
14.

Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.

Visvanathan S, Daniluk S, Ptaszyński R, Müller-Ladner U, Ramanujam M, Rosenstock B, Eleftheraki AG, Vinisko R, Petříková A, Kellner H, Dokoupilova E, Kwiatkowska B, Alten R, Schwabe C, Baum P, Joseph D, Fine JS, Padula SJ, Steffgen J.

Ann Rheum Dis. 2019 Jun;78(6):754-760. doi: 10.1136/annrheumdis-2018-214729. Epub 2019 Mar 22.

15.

Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.

Alten R, Mariette X, Lorenz HM, Nüßlein H, Galeazzi M, Navarro F, Chartier M, Heitzmann J, Poncet C, Rauch C, Le Bars M.

Clin Rheumatol. 2019 May;38(5):1413-1424. doi: 10.1007/s10067-019-04449-w. Epub 2019 Feb 21. Erratum in: Clin Rheumatol. 2019 Apr 11;:.

PMID:
30790095
16.

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group.

Pickles T, Alten R, Boers M, Bykerk V, Christensen J, Christensen R, van Hoogstraten H, Simon LS, Tam LS, Choy EH.

J Rheumatol. 2019 Oct;46(10):1406-1408. doi: 10.3899/jrheum.181054. Epub 2019 Feb 15.

PMID:
30770514
17.

Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study.

Alten R, Conaghan PG, Strand V, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Deodhar A.

Clin Rheumatol. 2019 Jun;38(6):1615-1626. doi: 10.1007/s10067-019-04446-z. Epub 2019 Feb 4.

18.

OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.

Toupin-April K, Barton JL, Fraenkel L, Meara A, Li LC, Brooks P, de Wit M, Stacey D, Légaré F, Shea B, Lyddiatt A, Hofstetter C, Christensen R, Scholte Voshaar M, Suarez-Almazor ME, Boonen A, Meade T, March L, Jull JE, Campbell W, Alten R, Karuranga S, Morgan EM, Kelly A, Kaufman J, Hill S, Maxwell LJ, Beaton D, El-Miedany Y, Mittoo S, Bartlett SJ, Singh JA, Tugwell PS.

J Rheumatol. 2019 Oct;46(10):1409-1414. doi: 10.3899/jrheum.181071. Epub 2019 Feb 1.

19.

Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.

Gulácsi L, Zrubka Z, Brodszky V, Rencz F, Alten R, Szekanecz Z, Péntek M.

Adv Ther. 2019 Mar;36(3):721-745. doi: 10.1007/s12325-018-0869-8. Epub 2019 Jan 12.

PMID:
30637590
20.

New concepts to reduce glucocorticoid toxicity.

Alten R, Mischkewitz M.

Joint Bone Spine. 2019 Nov;86(6):715-723. doi: 10.1016/j.jbspin.2018.11.006. Epub 2018 Dec 5.

PMID:
30528678
21.

Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.

Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, Figueiredo C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Lorenz HM, Nüsslein H, Alten R, Henes J, Krüger K, Schett G, Rech J.

J Rheumatol. 2019 May;46(5):460-466. doi: 10.3899/jrheum.180028. Epub 2018 Dec 1.

PMID:
30504510
22.

Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice.

Taylor PC, Alten R, Reino JJG, Caporali R, Bertin P, Sullivan E, Wood R, Piercy J, Vasilescu R, Spurden D, Alvir J, Tarallo M.

Patient Prefer Adherence. 2018 Oct 4;12:2007-2014. doi: 10.2147/PPA.S170054. eCollection 2018.

23.

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.

Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, van den Hoogen F, Pavelka K, Vulto AG.

BioDrugs. 2018 Oct;32(5):397-404. doi: 10.1007/s40259-018-0306-1.

24.

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.

Fleischmann RM, Alten R, Pileckyte M, Lobello K, Hua SY, Cronenberger C, Alvarez D, Bock AE, Sewell KL.

Arthritis Res Ther. 2018 Aug 15;20(1):178. doi: 10.1186/s13075-018-1676-y.

25.

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.

Cohen SB, Alten R, Kameda H, Hala T, Radominski SC, Rehman MI, Palaparthy R, Schumacher K, Schmitt S, Hua SY, Ianos C, Sewell KL.

Arthritis Res Ther. 2018 Jul 27;20(1):155. doi: 10.1186/s13075-018-1646-4.

26.

[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K.

Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y. Review. German.

PMID:
29968101
27.

Mechanism of Chemical and Electrochemical N2 Splitting by a Rhenium Pincer Complex.

Lindley BM, van Alten RS, Finger M, Schendzielorz F, Würtele C, Miller AJM, Siewert I, Schneider S.

J Am Chem Soc. 2018 Jun 27;140(25):7922-7935. doi: 10.1021/jacs.8b03755. Epub 2018 Jun 19.

28.

Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.

Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R.

J Rheumatol. 2018 Aug;45(8):1085-1092. doi: 10.3899/jrheum.170344. Epub 2018 Apr 15.

29.

Retention and clinical response to abatacept in patients with rheumatoid arthritis: an Italian perspective.

Galeazzi M, Alten R, Chartier M, Elbez Y, Fusaro E, Le Bars M, Lorenz HM, Pagano Mariano G, Muratore M, Nüßlein HG, Patanè G.

Clin Exp Rheumatol. 2018 Sep-Oct;36(5):935-936. Epub 2018 Mar 21. No abstract available.

30.

Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment.

Taylor PC, Alten R, Gomez-Reino JJ, Caporali R, Bertin P, Sullivan E, Wood R, Piercy J, Vasilescu R, Spurden D, Alvir J, Tarallo M.

RMD Open. 2018 Mar 17;4(1):e000615. doi: 10.1136/rmdopen-2017-000615. eCollection 2018.

31.

Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.

Kelly A, Tong A, Tymms K, March L, Craig JC, De Vera M, Evans V, Hassett G, Toupin-April K, van den Bemt B, Teixeira-Pinto A, Alten R, Bartlett SJ, Campbell W, Dawson T, Gill M, Hebing R, Meara A, Nieuwlaat R, Shaw Y, Singh JA, Suarez-Almazor M, Sumpton D, Wong P, Christensen R, Beaton D, de Wit M, Tugwell P; OMERACT-Adherence Group.

Trials. 2018 Mar 27;19(1):204. doi: 10.1186/s13063-018-2565-z.

32.

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis.

Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, Holzkaemper T, Fakhouri W, Taylor PC.

Rheumatol Int. 2018 Jun;38(6):935-947. doi: 10.1007/s00296-018-4005-5. Epub 2018 Mar 21. Review.

33.

Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.

Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nüßlein HG, Chartier M, Elbez Y, Rauch C, Le Bars M.

RMD Open. 2017 Dec 29;3(2):e000538. doi: 10.1136/rmdopen-2017-000538. eCollection 2017.

34.

[Autoimmune reactions to immune checkpoint inhibitors].

Pönisch W, Alten R, Baerwald C.

Z Rheumatol. 2017 Oct;76(Suppl 2):57-62. doi: 10.1007/s00393-017-0368-3. Review. German.

PMID:
29330759
35.

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.

Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll RE, Elbez Y, Rauch C.

Arthritis Res Ther. 2018 Jan 2;20(1):1. doi: 10.1186/s13075-017-1488-5.

37.

Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.

Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K.

Rheumatology (Oxford). 2017 Dec 1;56(12):2170-2178. doi: 10.1093/rheumatology/kex350.

PMID:
29029210
38.

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.

D'Agostino MA, Alten R, Mysler E, Le Bars M, Ye J, Murthy B, Heitzmann J, Vadanici R, Ferraccioli G.

Clin Rheumatol. 2017 Dec;36(12):2655-2665. doi: 10.1007/s10067-017-3788-1. Epub 2017 Aug 18.

39.

Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2017 Oct;44(10):1536-1543. doi: 10.3899/jrheum.161145. Epub 2017 Aug 15.

40.

Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting.

Toupin-April K, Barton J, Fraenkel L, Li LC, Brooks P, De Wit M, Stacey D, Légaré F, Meara A, Shea B, Lyddiatt A, Hofstetter C, Gossec L, Christensen R, Scholte-Voshaar M, Suarez-Almazor ME, Boonen A, Meade T, March L, Pohl C, Jull JE, Sivarajah S, Campbell W, Alten R, Karuranga S, Morgan E, Kaufman J, Hill S, Maxwell LJ, Welch V, Beaton D, El-Miedany Y, Tugwell PS.

J Rheumatol. 2017 Oct;44(10):1544-1550. doi: 10.3899/jrheum.161241. Epub 2017 Aug 1.

41.

Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.

Genovese MC, Kremer JM, van Vollenhoven RF, Alten R, Scali JJ, Kelman A, Dimonaco S, Brockwell L.

Arthritis Rheumatol. 2017 Sep;69(9):1751-1761. doi: 10.1002/art.40176. Epub 2017 Aug 1.

42.

Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study.

Khan NA, Spencer HJ, Nikiphorou E, Naranjo A, Alten R, Chirieac RM, Drosos AA, Géher P, Inanc N, Kerzberg E, Ancuta CM, Müller R, Ørnbjerg L, Sokka T.

Rheumatology (Oxford). 2017 Aug 1;56(8):1395-1400. doi: 10.1093/rheumatology/kex076.

PMID:
28575509
43.

[Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].

Sommer C, Alten R, Bär KJ, Bernateck M, Brückle W, Friedel E, Henningsen P, Petzke F, Tölle T, Üçeyler N, Winkelmann A, Häuser W.

Schmerz. 2017 Jun;31(3):274-284. doi: 10.1007/s00482-017-0207-0. Review. German.

PMID:
28493231
44.

An OMERACT Initiative Toward Consensus to Identify and Characterize Candidate Contextual Factors: Report from the Contextual Factors Working Group.

Finger ME, Boonen A, Woodworth TG, Escorpizo R, Christensen R, Nielsen SM, Leong AL, Scholte Voshaar M, Flurey CA, Milman N, Verstappen SM, Alten R, Guillemin F, Kloppenburg M, Beaton DE, Tugwell PS, March LM, Furst DE, Pohl C.

J Rheumatol. 2017 Nov;44(11):1734-1739. doi: 10.3899/jrheum.161200. Epub 2017 May 1.

PMID:
28461648
45.

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.

Fleischmann R, van Vollenhoven RF, Vencovský J, Alten R, Davies O, Mountian I, de Longueville M, Carter D, Choy E.

Rheumatol Ther. 2017 Jun;4(1):57-69. doi: 10.1007/s40744-017-0060-8. Epub 2017 Mar 28.

46.

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study.

Alten R, Nüßlein HG, Mariette X, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M.

RMD Open. 2017 Feb 13;3(1):e000345. doi: 10.1136/rmdopen-2016-000345. eCollection 2017.

47.

[Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF].

Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüsslein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche AK, Braun J.

Z Rheumatol. 2017 Mar;76(2):118-124. doi: 10.1007/s00393-016-0249-1. Review. German.

PMID:
28078432
48.

The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.

Mariette X, Alten R, Nüßlein HG, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M.

Joint Bone Spine. 2017 Oct;84(5):571-576. doi: 10.1016/j.jbspin.2016.10.011. Epub 2016 Dec 30.

49.

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).

Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P.

Ann Rheum Dis. 2017 Jun;76(6):998-1008. doi: 10.1136/annrheumdis-2016-210104. Epub 2016 Dec 19.

50.

Stiffness Is the Cardinal Symptom of Inflammatory Musculoskeletal Diseases, Yet Still Variably Measured: Report from the OMERACT 2016 Stiffness Special Interest Group.

Halls S, Sinnathurai P, Hewlett S, Mackie SL, March L, Bartlett SJ, Bingham CO 3rd, Alten R, Campbell I, Hill CL, Holt RJ, Hughes R, Kirwan JR, Leong AL, Leung YY, Lyddiatt A, Neill L, Orbai AM.

J Rheumatol. 2017 Dec;44(12):1904-1910. doi: 10.3899/jrheum.161073. Epub 2016 Dec 15.

Supplemental Content

Support Center